KR102494172B1 - 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 - Google Patents

정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 Download PDF

Info

Publication number
KR102494172B1
KR102494172B1 KR1020187033030A KR20187033030A KR102494172B1 KR 102494172 B1 KR102494172 B1 KR 102494172B1 KR 1020187033030 A KR1020187033030 A KR 1020187033030A KR 20187033030 A KR20187033030 A KR 20187033030A KR 102494172 B1 KR102494172 B1 KR 102494172B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
cells
compound
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033030A
Other languages
English (en)
Korean (ko)
Other versions
KR20180130575A (ko
Inventor
마리아 빌렌칙
마이클 프라이드
알렉산드라 쿠즈넷소바
유리이 간킨
마크 듀이
Original Assignee
펠리시텍스 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펠리시텍스 쎄라퓨틱스, 인코포레이티드 filed Critical 펠리시텍스 쎄라퓨틱스, 인코포레이티드
Priority to KR1020237002817A priority Critical patent/KR20230020560A/ko
Publication of KR20180130575A publication Critical patent/KR20180130575A/ko
Application granted granted Critical
Publication of KR102494172B1 publication Critical patent/KR102494172B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187033030A 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 Active KR102494172B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237002817A KR20230020560A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323583P 2016-04-15 2016-04-15
US62/323,583 2016-04-15
PCT/US2017/027734 WO2017181087A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002817A Division KR20230020560A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Publications (2)

Publication Number Publication Date
KR20180130575A KR20180130575A (ko) 2018-12-07
KR102494172B1 true KR102494172B1 (ko) 2023-02-02

Family

ID=60039311

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187033030A Active KR102494172B1 (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
KR1020237002817A Ceased KR20230020560A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237002817A Ceased KR20230020560A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Country Status (11)

Country Link
US (3) US10314843B2 (enExample)
EP (1) EP3443351A4 (enExample)
JP (1) JP7278776B2 (enExample)
KR (2) KR102494172B1 (enExample)
CN (1) CN109313197A (enExample)
AU (2) AU2017248807A1 (enExample)
BR (1) BR112018071023A2 (enExample)
CA (1) CA3020978A1 (enExample)
IL (2) IL292475A (enExample)
MX (2) MX2018012508A (enExample)
WO (1) WO2017181087A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) * 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2475368B1 (en) * 2009-09-11 2014-12-17 Amgen, Inc N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
FR2993317B1 (fr) 2012-07-16 2014-08-15 Snecma Carter de turbomachine dans un materiau composite et procede de fabrication associe
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
US9566280B2 (en) * 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
MA39763A (fr) 2014-03-20 2017-01-25 Samumed Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
CN108135871B (zh) * 2015-07-23 2022-11-04 博蔚医药生物科技股份有限公司 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) * 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Daina Z. Ewton, et al., Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells, Molecular Cancer Therapeutics, 2011, 10(11), 2104-2114. (2011.08.30.)*

Also Published As

Publication number Publication date
KR20230020560A (ko) 2023-02-10
KR20180130575A (ko) 2018-12-07
CA3020978A1 (en) 2017-10-19
EP3443351A1 (en) 2019-02-20
MX2022012146A (es) 2022-10-21
US20220110941A1 (en) 2022-04-14
IL262325A (en) 2018-11-29
IL262325B (en) 2022-06-01
BR112018071023A2 (pt) 2019-02-05
AU2017248807A1 (en) 2018-10-25
IL292475A (en) 2022-06-01
US10314843B2 (en) 2019-06-11
EP3443351A4 (en) 2019-12-18
US20190290651A1 (en) 2019-09-26
CN109313197A (zh) 2019-02-05
MX2018012508A (es) 2019-07-08
WO2017181087A1 (en) 2017-10-19
AU2023214240A1 (en) 2023-08-24
JP7278776B2 (ja) 2023-05-22
US20170296542A1 (en) 2017-10-19
JP2019511553A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
KR102494172B1 (ko) 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
KR102494174B1 (ko) 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합
US8138356B2 (en) Chemical inhibitors of inhibitors of differentiation
Berte et al. Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
Zheng et al. Simultaneous NF‐κB inhibition and E‐cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
US20220073519A1 (en) Compounds For Repressing Cancer Cell Growth
AU2013235275A1 (en) Methods of treating cancer using aurora kinase inhibitors
MX2024013264A (es) Compuestos de 7-(pirimidin-4-il)quinolin-4(1h)-ona sustituidos como inhibidores de cinasas dependientes de ciclina
EP3200794A1 (en) A compound for anti-cancer therapy that acts by targeting gof mutant p53 and stimulates p73
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
JP2025530417A (ja) 腫瘍の予防・治療薬及びその用途
WO2017069913A1 (en) Chalcone compounds
WO2011131636A1 (en) Combined treatment of cancer with benzo[e]pyridoindoles and dna-damaging agents
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601